abstract |
The present invention provides a Vγ9Vδ2 T cell modified by MUC1-Tn chimeric antigen receptor and its application. Specifically, the present invention provides CAR-Vγ9Vδ2 T cells targeting MUC1-Tn, which have strong specific cytotoxic effects on various tumor cells in vitro, and their cytotoxic effects are stronger than CAR-αβ T cells. Moreover, the addition of IL-2 in vitro can enhance the cytotoxicity of CAR-Vγ9Vδ2 T cells and improve the persistence of their cytotoxic function, providing a promising allogeneic cellular immunotherapy strategy for solid tumors. |